News

 

NEWS

QB3@953 facilitates strategic alliance between innovative start up member and a sponsor company

QB3@953 facilitates strategic alliance between innovative start up member and a sponsor company Telo Therapeutics enters into an Oncology-focused research collaboration with GSK San Francisco, CA, Feb 2, 2017 – QB3@953, the Bay Area’s premier life science incubator, today announced the collaboration between one of its member companies, Telo Therapeutics, and one of its sponsor companies, GlaxoSmithKline (GSK). Telo Therapeutics […]

Read more

Servier partners with QB3@953 to find and cultivate innovative startups

Servier is the second largest French pharmaceutical company with over 3,000 researchers focused on novel treatments for cardiovascular disease, oncology, diabetes, CNS, and Rheumatology. This partnership is a boon for researchers on both sides of the Atlantic, bringing together Servier’s decades of expertise and QB3@953’s innovative thinking and startup community. Servier will receive a “golden ticket,” which allows Servier to […]

Read more

Top Place in the First Annual Diabetes Innovation Challenge

Top Place in the First Annual Diabetes Innovation Challenge Enable Biosciences was awarded top place in the First Annual Diabetes Innovation Challenge held in Boston for the most innovative late-stage (pre-clinical through translational) technology for their breakthrough ultra-sensitivity antibody assay platform. Press Release

Read more

LogicInk – Is the future of wearable health tech ….TATTOOS?

Is the future of wearable health tech ….TATTOOS? A Talk at Techonomy On November 9th 2016, LogicInk gave their first public talk as a company at a conference called Techonomy in Half Moon Bay, CA. What happens when low-cost biosensors embedded in tattoos can detect blood alcohol, sugar, or biomarkers related to diseases like malaria or zika? How will that […]

Read more

Nucleo Life Sciences

Nucleo Life Sciences will be expanding their team to broaden the number of formulation and drug development projects they are tackling. Borne out of Actera, another former QB3@953 company, Nucleo Life Sciences incubated with us for a little over one year before outgrowing our location.

Read more

Perlara PBC Announces Pharma Collaboration with Novartis

Perlara PBC Announces Pharma Collaboration with Novartis SAN FRANCISCO, Oct. 19, 2016 /PRNewswire/ Perlara PBC (previously Perlstein Lab PBC) today announced the formation of a drug discovery and development collaboration with Novartis to identify new definitive therapeutics for lysosomal storage disorders, starting with lead program Niemann-Pick Type C Disease. In addition to the collaboration, Novartis has made an equity investment […]

Read more

Amgen Incubators Grow Startup for Harvest

Amgen Incubators Grow Startup for Harvest Venture division seeks access to technology, potential takeovers. San Fernando Valley Business Journal, July 11-24, 2016 By STEPHANIE HENKEL, Staff Reporter Amgen inc. hopes to get in on more ground floors by sponsoring startups in the biotech hubs in Cambridge, Mass. and, more recently, in San Francisco. The Thousand Oaks biopharmaceutical company last month […]

Read more

Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration

Kite Pharma and Cell Design Labs Announce Exclusive Research Collaboration Using Molecular ‘On/Off Switches’ for CAR T-Cell Immunotherapies Kite to License Cell Design Labs’ Synthetic Biology Technology for Applications in Acute Myeloid Leukemia with Exclusive Option for Applications in B-cell Malignancies Cell Design Labs’ Reversible ‘On/Off Switch’ Technology Provides Dynamic Range of Control to Precisely Regulate Activity of Engineered CAR […]

Read more

Cell Design Labs Executes Series of Private Financings

Cell Design Labs Executes Series of Private Financings New Company Focused on Discovering and Developing Next-Generation Immunotherapies for Cancer and Other Complex Diseases   SAN FRANCISCO, Calif. June 2, 2016 — Cell Design Labs, Inc. today announced it has executed a staged series of investor and strategic partner financings totaling $34.4 million to fund the company’s start-up operations. The investors, […]

Read more

Avant Completes Acquisitions of Amarantus, Theranostics Health

Avant Completes Acquisitions of Amarantus and Theranostics Health Avant Diagnostics announced today that it has completed its previously announced acquisitions of Amarantus Diagnostics and protein analysis services provider Theranostics Health. In January, Scottsdale, Arizona-based Avant inked a deal to merge with Amarantus Diagnostics, a subsidiary of therapeutics developer Amarantus Bioscience. The arrangement joins Amarantus’ research-use-only assays for multiple sclerosis and […]

Read more
Page 4 of 10« First...23456...10...Last »

Upcoming Event

  • Office Hours with WSGR Patent and Corporate Law

    09:00-11:00
    03/01/2018
    To apply for Office Hours contact: Carol Ochoa Sponsored by:
    Ali Alemozafar Dr. Ali R. Alemozafar is a senior associate at Wilson Sonsini Goodrich & Rosati, where he focuses on patent prosecution, strategic patent counseling, and IP due diligence in a wide range of technical fields, including diagnostics, therapeutics, genomics, and materials. Ali received his Ph.D. in chemical engineering at Stanford University, where he investigated the reactivity and atomic-scale changes accompanying reactions on various catalysts. During his postdoctoral research fellowship at the Department of Chemistry and Chemical Biology at Harvard University, he investigated the dynamics of TiOx nanoparticles and the use of gold as an oxidation catalyst. Prior to attending law school, Ali worked on data warehousing, business intelligence, and enterprise data integration. Ali frequently lectures at the UC Berkeley School of Law and UC Hastings College of the Law on various intellectual property topics, including patent strategy and IP due diligence. Michael Hostetler Dr. Mike Hostetler is a partner in the SOMA and San Diego offices of Wilson Sonsini Goodrich & Rosati, where he provides strategic intellectual property counseling to more than 100 growth enterprises in the pharmaceutical and biotechnology, and information technology industries. He works with both venture-backed and public companies. His expertise includes patent strategy, patent prosecution, and patent diligence (both buy and sell side) for venture financings, public offerings, and mergers and acquisitions. He has provided patent counseling in support of pharmaceutical and biotechnology, and information technology products in all stages of development, from proof of concept to regulatory approval to product launch. He leads a talented team of patent associates and patent agents that can meet virtually any technical and strategic need. Mike currently serves as a member of the firm's Policy and Nominating Committees. Elton Satusky Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. He specializes in public and private corporate finance and corporate law and governance. Elton also has considerable expertise in the areas of mergers and acquisitions and venture capital.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter